Elisabeth Willers, MD
Pulmonary Disease · Nashville, TNNPI 1043300288
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,250 of the $14,040 with a category attached, or 65.9%. Inari Medical, Inc. accounts for 66.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $10,657 and has fallen 96.7% since, to $354 in 2024.
Across 209 payments — averaging $67.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$9K
- GSK$1K
- Genentech, Inc.$1K
- Insmed, Inc.$666
- AstraZeneca$358
- Actelion Pharmaceuticals US, Inc.$256
- plus $1K from 17 others
Across 10 payments — averaging $3152.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$32K
What the payments were for
- Consulting fees$9,25066%
- Grants$1,0007%
- Food & beverage$3,59726%
- Education$1931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 8 | $9,336 |
| GSK | 88 | $1,208 |
| Genentech, Inc. | 1 | $1,000 |
| Insmed, Inc. | 25 | $666 |
| AstraZeneca | 18 | $358 |
| Actelion Pharmaceuticals US, Inc. | 16 | $256 |
| Pfizer | 12 | $208 |
| Penumbra, Inc. | 1 | $169 |
| Regeneron Healthcare Solutions, Inc. | 7 | $145 |
| Sanofi | 6 | $135 |
| Boehringer Ingelheim | 7 | $127 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Mylan Specialty L.p. | 4 | $64 |
| Novartis | 3 | $51 |
| Johnson & Johnson | 2 | $40 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Electromed, Inc. | 1 | $21 |
| Amgen | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$18,500
- Indigo System$169
How this compares
$14,040 in reported general payments places this provider in the 80th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $215,876 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $72,204 |
| TezspireTezepelumab-Ekko | 14 | $61,984 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $42,729 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 73 | $39,969 |
| Spiriva RespimatTiotropium Bromide | 45 | $27,219 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $15,096 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $13,865 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $13,136 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $10,986 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $8,133 |
| Wixela InhubFluticasone Propion/Salmeterol | 40 | $7,044 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 180 | $6,324 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $5,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,208 | $287,566392 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $358 | $147,324149 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $127 | $75,321132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Lisa LancasterNashville$519K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Joao DeandradeNashville$245K
- Anna HemnesNashville$183K
- Bryan HayNashville$126K
- Karl KuhnNashville$106K
- Fabien MaldonadoNashville$83K
- Margaret SalisburyNashville$53K
- Victor KhaNashville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.